RxDoctor Payments Data

Nadia Stoilova-Karanfilov, MD

Internal Medicine · Columbus, OHNPI 1013202357

Payments from drug & device makers

$6,388in general payments, 2019–2025

Across 289 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$875
  • AstraZeneca$741
  • Novo Nordisk$631
  • Lilly USA, LLC$492
  • Pfizer$392
  • GSK$326
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,364100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,388 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$61,121
Medicare patients
141
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$79,696
MounjaroTirzepatide57$74,303
OzempicSemaglutide45$67,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$39,015
JanuviaSitagliptin Phosphate19$22,948
JardianceEmpagliflozin11$19,437
RybelsusSemaglutide12$15,395
XareltoRivaroxaban15$12,623
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$9,409
Atorvastatin Calcium458$4,763
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$3,240
Gabapentin180$3,083
Albuterol Sulfate HfaAlbuterol Sulfate102$2,767
SynthroidLevothyroxine Sodium34$2,705
SymbicortBudesonide/Formoterol Fumarate12$2,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$631$83,28457 claims
PfizerEliquis, Paxlovid$392$81,10998 claims
Lilly USA, LLCMounjaro$492$74,30357 claims
GSKTrelegy Ellipta$326$39,01552 claims
MerckJanuvia$212$22,94819 claims
Boehringer IngelheimJardiance$292$19,43711 claims
AbbVieSynthroid$875$2,70534 claims
AstraZenecaSymbicort$741$2,66912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →